ReviewNanomaterials (Basel, Switzerland)2020
Advances in the Design of pH-Sensitive Cubosome Liquid Crystalline Nanocarriers for Drug Delivery Applications.
Review in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 107 citations in OpenAlex.
- Advances in Cubosome-Based Transdermal Delivery: Structural Design, Manufacturing, and Engineering Strategies.ACS omega · 2026Review
- Designed Liquid Crystalline Nanoassemblies From Clinically Validated Polyunsaturated Lipids for Combined Antioxidant, Anti-Apoptotic, and Neurotrophic Treatments.Advanced healthcare materials · 2026Article
- Ophthalmic-targeted brinzolamide-laden cubosomal solid lipid nano-vesicular system (Cube-SLNV): design, development, and in vitro and ex vivo characterization.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dynamic Self-Assembly and Stimuli-Responsive Disassembly of Bioactive-Loaded Cubosomes in Biomimetic Media Traced by Real-Time Small-Angle X-ray Scattering and Cryogenic Transmission Electron Microscopy.ACS applied materials & interfaces · 2025Article
- Responsive Nano-structured Cubosomes: Advancements and Therapeutic Applications.Advanced pharmaceutical bulletin · 2025Review
- An Insight into Cubosomal Drug Delivery Approaches: An Explicative Review.Pharmaceutical nanotechnology · 2025Review
- Liquid Crystalline Lipid Nanoparticles: Emerging Trends and Applications in Skin Cancer.Pharmaceutical nanotechnology · 2025Review
- Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.Pharmaceutics · 2024Review
- A Synoptic Update on Smart Lipid Nanocarrier: Cubosomes, and their Design Development, and Recent Challenges.Current pharmaceutical biotechnology · 2024Article
- Self-Assembled Polymers for Gastrointestinal Tract Targeted Delivery through the Oral Route: An Update.Polymers · 2023Review
- Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems.Pharmaceutics · 2023Review
- Small-volumeInternational journal of pharmaceutics: X · 2022Article
- Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle EmitterMolecular pharmaceutics · 2022Article
- Short-Chain Mono-Alkyl β-D-Glucoside Crystals-Do They Form a Cubic Crystal Structure?Molecules (Basel, Switzerland) · 2022Article
- Inverse ISAsomes in Bio-Compatible Oils-Exploring Formulations in Squalane, Triolein and Olive Oil.Nanomaterials (Basel, Switzerland) · 2022Article
- Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases.Pharmaceutics · 2021Review
- Cubosome Based Ion-Selective Optodes-Toward Tunable Biocompatible Sensors.Analytical chemistry · 2021Article
- Cubic and Hexagonal Mesophases for Protein Encapsulation: Structural Effects of Insulin Confinement.Langmuir : the ACS journal of surfaces and colloids · 2021Article
- Development and Characterization ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Novel Amphiphilic Block Copolymers for the Formation of Stimuli-Responsive Non-Lamellar Lipid Nanoparticles.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanostructure bicontinuous cubic phase self-assembled materials are receiving expanding applications as biocompatible delivery systems in various therapeutic fields. The functionalization of cubosome, spongosome, hexosome and liposome nanocarriers by pH-sensitive lipids and/or pH-sensitive polymer shells offers new opportunities for oral and topical drug delivery towards a new generation of cancer therapies. The electrochemical behavior of drug compounds may favor pH-triggered drug release as well. Here, we highlight recent investigations, which explore the phase behavior of mixed nonlamellar lipid/fatty acid or phospholipid systems for the design of pH-responsive and mucoadhesive drug delivery systems with sustained-release properties. X-ray diffraction and small-angle X-ray scattering (SAXS) techniques are widely used in the development of innovative delivery assemblies through detailed structural analyses of multiple amphiphilic compositions from the lipid/co-lipid/water phase diagrams. pH-responsive nanoscale materials and nanoparticles are required for challenging therapeutic applications such as oral delivery of therapeutic proteins and peptides as well as of poorly water-soluble substances. Perspective nanomedicine developments with smart cubosome nanocarriers may exploit compositions elaborated to overcome the intestinal obstacles, dual-drug loaded pH-sensitive liquid crystalline architectures aiming at enhanced therapeutic efficacy, as well as composite (lipid/polyelectrolyte) types of mucoadhesive controlled release colloidal cubosomal formulations for the improvement of the drugs' bioavailability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.